Prothymosin α plays multifunctional cell robustness roles in genomic, epigenetic, and nongenomic mechanisms

Annals of the New York Academy of Sciences

Volumn 1269, Issue 1, 2012, Pages 34-43

  Ueda, Hiroshi ^a   Matsunaga, Hayato ^a   Halder, Sebok Kumar ^a  

^a NAGASAKI UNIVERSITY   (Japan)

Author keywords

Apaf 1; CBP p300; Estrogen receptor; Linker histone H1; Nrf2 Keap1; Toll like receptor 4

Indexed keywords

APOPTOSOME; CASPASE; ESTROGEN RECEPTOR; PROTHYMOSIN ALPHA;

APOPTOSIS; ARTICLE; CELL DIFFERENTIATION; CELL FUNCTION; CELL PROLIFERATION; CYTOSOL; DRUG MECHANISM; ENZYME ACTIVATION; EPIGENETICS; GENOMICS; NEUROPROTECTION;

EID: 84867365065     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2012.06675.x     Document Type: Article

References (65)

1. Haritos, A.A., J. Caldarella & B.L. Horecker 1985. Simultaneous isolation and determination of prothymosin alpha, parathymosin alpha, thymosin beta 4, and thymosin beta 10. Anal. Biochem. 144: 436-440.
2. Clinton, M., L. Graeve, H. el-Dorry, et al 1991. Evidence for nuclear targeting of prothymosin and parathymosin synthesized in situ. Proc. Natl. Acad. Sci. USA 88: 6608-6612.
3. Martini, P.G., R. Delage-Mourroux, D.M. Kraichely & B.S. Katzenellenbogen 2000. Prothymosin alpha selectively enhances estrogen receptor transcriptional activity by interacting with a repressor of estrogen receptor activity. Mol. Cell Biol. 20: 6224-6232.
4. Bianco, N.R. & M.M. Montano 2002. Regulation of prothymosin alpha by estrogen receptor alpha: molecular mechanisms and relevance in estrogen-mediated breast cell growth. Oncogene 21: 5233-5244.
5. Jiang, X., H.E. Kim, H. Shu, et al 2003. Distinctive roles of PHAP proteins and prothymosin-alpha in a death regulatory pathway. Science 299: 223-226.
6. Piñeiro, A., O.J. Cordero & M. Nogueira 2000. Fifteen years of prothymosin alpha: contradictory past and new horizons. Peptides 21: 1433-1446.
7. Mosoian, A., A. Teixeira, C.S. Burns, et al 2010. Prothymosin-alpha inhibits HIV-1 via Toll-like receptor 4-mediated type I interferon induction. Proc. Natl. Acad. Sci. USA 107: 10178-10183.
8. Mosoian, A. 2011. Intracellular and extracellular cytokine-like functions of prothymosin α: implications for the development of immunotherapies. Future Med. Chem. 3: 1199-1208.
9. Ueda, H., R. Fujita, A. Yoshida, et al 2007. Identification of prothymosin-alpha1, the necrosis-apoptosis switch molecule in cortical neuronal cultures. J. Cell Biol. 176: 853-862.
10. Ueda, H. 2009. Prothymosin alpha and cell death mode switch, a novel target for the prevention of cerebral ischemia-induced damage. Pharmacol. Ther. 123: 323-333.
11. Matsunaga, H. & H. Ueda 2010. Stress-induced non-vesicular release of prothymosin-á initiated by an interaction with S100A13, and its blockade by caspase-3 cleavage. Cell Death Differ 17: 1760-1772.
12. Gómez-Márquez, J. 2007. Function of prothymosin alpha in chromatin decondensation and expression of thymosin beta-4 linked to angiogenesis and synaptic plasticity. Ann. N.Y. Acad. Sci. 1112: 201-209.
13. Dominguez, F., C. Magdalena, E. Cancio, et al 1993. Tissue concentrations of prothymosin alpha: a novel proliferation index of primary breast cancer. Eur. J. Cancer 29A: 893-897.
14. Wu, C.G., N.A. Habib, R.R. Mitry, et al 1997. Overexpression of hepatic prothymosin alpha, a novel marker for human hepatocellular carcinoma. Br. J. Cancer 76: 1199-1204.
15. Magdalena, C., F. Dominguez, L. Loidi & J.L. Puente 2000. Tumour prothymosin alpha content, a potential prognostic marker for primary breast cancer. Br. J. Cancer 82: 584-590.
16. Sasaki, H., Y. Sato, S. Kondo, et al 2001. Expression of the prothymosin alpha mRNA correlated with that of N-myc in neuroblastoma. Cancer Lett. 168: 191-195.
17. Hapke, S., H. Kessler, B. Luber, et al 2003. Ovarian cancer cell proliferation and motility is induced by engagement of integrin alpha(v)beta3/Vitronectin interaction. Biol. Chem. 384: 1073-1083.
18. Shiwa, M., Y. Nishimura, R. Wakatabe, et al 2003. Rapid discovery and identification of a tissue-specific tumor biomarker from 39 human cancer cell lines using the SELDI ProteinChip platform. Biochem. Biophys. Res. Commun. 309: 18-25.
19. Leys, C.M., S. Nomura, B.J. LaFleur, et al 2007. Expression and prognostic significance of prothymosin-alpha and ERp57 in human gastric cancer. Surgery 141: 41-50.
20. Kashat, L., A. So, O. Masui, et al 2010. Secretome based Identification and Characterization of Potential Biomarkers in Thyroid Cancer. J. Proteome Res. 9: 5757-5769.
21. Gómez-Márquez, J., F. Segade, M. Dosil, et al 1989. The expression of prothymosin alpha gene in T lymphocytes and leukemic lymphoid cells is tied to lymphocyte proliferation. J. Biol. Chem. 264: 8451-8454.
22. Conteas, C.N., M.G. Mutchnick, K.C. Palmer, et al 1990. Cellular levels of thymosin immunoreactive peptides are linked to proliferative events: evidence for a nuclear site of action. Proc. Natl. Acad. Sci. USA 87: 3269-3273.
23. Smith, M.R., A. al-Katib, R. Mohammad, et al 1993. Prothymosin alpha gene expression correlates with proliferation, not differentiation, of HL-60 cells. Blood 82: 1127-1132.
24. Subramanian, C., S. Hasan, M. Rowe, et al 2002. Epstein-Barr virus nuclear antigen 3C and prothymosin alpha interact with the p300 transcriptional coactivator at the CH1 and CH3/HAT domains and cooperate in regulation of transcription and histone acetylation. J. Virol. 76: 4699-4708.
25. Karetsou, Z., A. Kretsovali, C. Murphy, et al 2002. Prothymosin alpha interacts with the CREB-binding protein and potentiates transcription. EMBO Rep. 3: 361-366.
26. Happel, N. & D. Doenecke 2009. Histone H1 and its isoforms: contribution to chromatin structure and function. Gene 431: 1-12.
27. Martini, P.G. & B.S. Katzenellenbogen 2003. Modulation of estrogen receptor activity by selective coregulators. J. Steroid Biochem. Mol. Biol. 85: 117-122.
28. Dhakshinamoorthy, S., D.J. Long & A.K. Jaiswal 2000. Antioxidant regulation of genes encoding enzymes that detoxify xenobiotics and carcinogens. Curr. Top Cell Regul. 36: 201-216.
29. Jaiswal, A.K. 2000. Regulation of genes encoding NAD(P)H:quinone oxidoreductases. Free Radic. Biol. Med. 29: 254-262.
30. Kobayashi, M. & M. Yamamoto 2006. Nrf2-Keap1 regulation of cellular defense mechanisms against electrophiles and reactive oxygen species. Adv. Enzyme Regul. 46: 113-140.
31. McMahon, M., N. Thomas, K. Itoh, et al 2006. Dimerization of substrate adaptors can facilitate cullin-mediated ubiquitylation of proteins by a "tethering" mechanism: a two-site interaction model for the Nrf2-Keap1 complex. J. Biol. Chem. 281: 24756-24768.
32. Karapetian, R.N., A.G. Evstafieva, I.S. Abaeva, et al 2005. Nuclear oncoprotein prothymosin alpha is a partner of Keap1: implications for expression of oxidative stress-protecting genes. Mol. Cell Biol. 25: 1089-1099.
33. Niture, S.K. & A.K. Jaiswal 2009. Prothymosin-alpha mediates nuclear import of the INrf2/Cul3 Rbx1 complex to degrade nuclear Nrf2. J. Biol. Chem. 284: 13856-13868.
34. Schafer, Z.T. & S. Kornbluth 2006. The apoptosome: physiological, developmental, and pathological modes of regulation. Dev. Cell 10: 549-561.
35. Reubold, T.F. & S. Eschenburg 2012. A molecular view on signal transduction by the apoptosome. Cell Signal 24: 1420-1425.
36. Qi, X., L. Wang & F. Du 2010. Novel Small Molecules Relieve Prothymosin alpha-Mediated Inhibition of Apoptosome Formation by Blocking Its Interaction with Apaf-1. Biochemistry 49: 1923-1930.
37. Evstafieva, A.G., G.A. Belov, M. Kalkum, et al 2000. Prothymosin alpha fragmentation in apoptosis. FEBS Lett. 467: 150-154.
38. Evstafieva, A.G., G.A. Belov, Y.P. Rubtsov, et al 2003. Apoptosis-related fragmentation, translocation, and properties of human prothymosin alpha. Exp. Cell Res. 284: 211-223.
39. Malicet, C., J.C. Dagorn, J.L. Neira & J.L. Iovanna 2006. p8 and prothymosin alpha: unity is strength. Cell Cycle 5: 829-830.
40. Malicet, C., V. Giroux, S. Vasseur, et al 2006. Regulation of apoptosis by the p8/prothymosin alpha complex. Proc. Natl. Acad. Sci. USA 103: 2671-2676.
41. 2+ channel activity regulates the interaction between FGF-1 and S100A13 for stress-induced non-vesicular release. Cell Mol. Neurobiol. 26: 237-246.
42. Matsunaga, H. & H. Ueda 2006. Evidence for serum-deprivation-induced co-release of FGF-1 and S100A13 from astrocytes. Neurochem. Int. 49: 294-303.
43. Yasuda, Y., Y. Miyamoto, T. Saiwaki & Y. Yoneda 2006. Mechanism of the stress-induced collapse of the Ran distribution. Exp. Cell Res. 312: 512-520.
44. Yasuhara, N., M. Oka & Y. Yoneda 2009. The role of the nuclear transport system in cell differentiation. Semin Cell Dev. Biol. 20: 590-599.
45. Fujita, R. & H. Ueda 2003. Protein kinase C-mediated necrosis-apoptosis switch of cortical neurons by conditioned medium factors secreted under the serum-free stress. Cell Death Differ 10: 782-790.
46. Fujita, R. & H. Ueda 2003. Protein kinase C-mediated cell death mode switch induced by high glucose. Cell Death Differ 10: 1336-1347.
47. Kaplan, D.R. & F.D. Miller 2000. Neurotrophin signal transduction in the nervous system. Curr. Opin. Neurobiol. 10: 381-391.
48. Ay, I., H. Sugimori & S.P. Finklestein 2001. Intravenous basic fibroblast growth factor (bFGF) decreases DNA fragmentation and prevents downregulation of Bcl-2 expression in the ischemic brain following middle cerebral artery occlusion in rats. Brain Res. Mol. Brain Res. 87: 71-80.
49. Patapoutian, A. & L.F. Reichardt 2001. Trk receptors: mediators of neurotrophin action. Curr. Opin. Neurobiol. 11: 272-280.
50. Sofroniew, M.V., C.L. Howe & W.C. Mobley 2001. Nerve growth factor signaling, neuroprotection, and neural repair. Annu. Rev. Neurosci. 24: 1217-1281.
51. Yamashita, T., K. Sawamoto, S. Suzuki, et al 2005. Blockade of interleukin-6 signaling aggravates ischemic cerebral damage in mice: possible involvement of Stat3 activation in the protection of neurons. J. Neurochem. 94: 459-468.
52. Yoshida, T., I. Tomioka, T. Nagahara, et al 2004. Bax-inhibiting peptide derived from mouse and rat Ku70. Biochem. Biophys. Res. Commun. 321: 961-966.
53. Fujita R. & H. Ueda 2007. Prothymosin-alpha1 prevents necrosis and apoptosis following stroke. Cell Death Differ 14: 1839-1842.
54. Fujita, R., M. Ueda, K. Fujiwara & H. Ueda 2009. Prothymosin-alpha plays a defensive role in retinal ischemia through necrosis and apoptosis inhibition. Cell Death Differ 16: 349-358.
55. Stevens, S.L., P.Y. Leung, K.B. Vartanian, et al 2011. Multiple preconditioning paradigms converge on interferon regulatory factor-dependent signaling to promote tolerance to ischemic brain injury. J. Neurosci. 31: 8456-8463.
56. Vartanian, K.B., S.L. Stevens, B.J. Marsh, et al 2011. LPS preconditioning redirects TLR signaling following stroke: TRIF-IRF3 plays a seminal role in mediating tolerance to ischemic injury. J. Neuroinflammation 8: 140.
57. Leung, P.Y., S.L. Stevens, A.E. Packard, et al 2012. Toll-like receptor 7 preconditioning induces robust neuroprotection against stroke by a novel type I interferon-mediated mechanism. Stroke 43: 1383-1389.
58. Marsh, B., S.L. Stevens, A.E. Packard, et al 2009. Systemic lipopolysaccharide protects the brain from ischemic injury by reprogramming the response of the brain to stroke: a critical role for IRF3. J. Neurosci. 29: 9839-9849.
59. Fan, H., B. Zingarelli, O.M. Peck, et al 2005. Lipopolysaccharide- and gram-positive bacteria-induced cellular inflammatory responses: role of heterotrimeric Galpha(i) proteins. Am. J. Physiol. Cell Physiol. 289: C293-C301.
60. Cuschieri, J., J. Billgren & R.V. Maier 2006. Phosphatidylcholine-specific phospholipase C (PC-PLC) is required for LPS-mediated macrophage activation through CD14. J. Leukoc. Biol. 80: 407-414.
61. Dauphinee, S.M., V. Voelcker, Z. Tebaykina, et al 2011. Heterotrimeric Gi/Go proteins modulate endothelial TLR signaling independent of the MyD88-dependent pathway. Am. J. Physiol. Heart Circ. Physiol. 301: H2246-H2253.
62. Grünberg, E., K. Eckert, H.R. Maurer, et al 1997. Prothymosin alpha1 effects on IL-2-induced expression of LFA-1 on lymphocytes and their adhesion to human umbilical vein endothelial cells. J. Interferon. Cytokine Res. 17: 159-165.
63. Heidecke, H., K. Eckert, K. Schulze-Forster & H.R. Maurer 1997. Prothymosin alpha 1 effects in vitro on chemotaxis, cytotoxicity and oxidative response of neutrophils from melanoma, colorectal and breast tumor patients. Int. J. Immunopharmacol. 19: 413-420.
64. Moody, T.W., J. Leyton, F. Zia, et al 2000. Thymosinalpha1 is chemopreventive for lung adenoma formation in A/J mice. Cancer Lett. 155: 121-127.
65. Romani, L., F. Bistoni, C. Montagnoli, et al 2007. Thymosin alpha1: an endogenous regulator of inflammation, immunity, and tolerance. Ann. N.Y. Acad. Sci. 1112: 326-338.